Similarly, our group and others have demonstrated decreased IGF-1 serum levels in insulin-resistant and NAFLD-patients that correlates significantly with liver lobular inflammation and fibrosis, even after adjusting by body mass index [16,17,18,19]. Here, IGF1 is linked to metabolic dysfunction-associated steatotic liver disease.